Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

A. Khattak; C. Robert; C. U. Blank; M. Mandala; G. V. Long; V. Atkinson; S. Dalle; A. Haydon; M. Lichinitser; M. S. Carlino; S. Sandhu; J. Larkin; S. Puig; P. A. Ascierto; P. Rutkowski; D. Schadendorf; P. Lorigan; N. Ibrahim; S. Suciu; A. M. M. Eggermont

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

A. Khattak, C. Robert, C. U. Blank, M. Mandala, G. V. Long, V. Atkinson, S. Dalle, A. Haydon, M. Lichinitser, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, P. Lorigan, N. Ibrahim, S. Suciu, A. M. M. Eggermont

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	48-48
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	14
Publication status	Published - Aug 2018

Cite this

Khattak, A., Robert, C., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Lorigan, P., Ibrahim, N., Suciu, S., & Eggermont, A. M. M. (2018). Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma. Asia-Pacific Journal of Clinical Oncology, 14, 48-48.

Khattak, A. ; Robert, C. ; Blank, C. U. ; Mandala, M. ; Long, G. V. ; Atkinson, V. ; Dalle, S. ; Haydon, A. ; Lichinitser, M. ; Carlino, M. S. ; Sandhu, S. ; Larkin, J. ; Puig, S. ; Ascierto, P. A. ; Rutkowski, P. ; Schadendorf, D. ; Lorigan, P. ; Ibrahim, N. ; Suciu, S. ; Eggermont, A. M. M. / Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results : Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma. In: Asia-Pacific Journal of Clinical Oncology. 2018 ; Vol. 14. pp. 48-48.

@article{b53d212bff174dc3bbc36ee28a80fd96,

title = "Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma",

author = "A. Khattak and C. Robert and Blank, {C. U.} and M. Mandala and Long, {G. V.} and V. Atkinson and S. Dalle and A. Haydon and M. Lichinitser and Carlino, {M. S.} and S. Sandhu and J. Larkin and S. Puig and Ascierto, {P. A.} and P. Rutkowski and D. Schadendorf and P. Lorigan and N. Ibrahim and S. Suciu and Eggermont, {A. M. M.}",

year = "2018",

month = aug,

language = "English",

volume = "14",

pages = "48--48",

journal = "Asia–Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "John Wiley & Sons",

}

Khattak, A, Robert, C, Blank, CU, Mandala, M, Long, GV, Atkinson, V, Dalle, S, Haydon, A, Lichinitser, M, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Lorigan, P, Ibrahim, N, Suciu, S & Eggermont, AMM 2018, 'Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 48-48.

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results : Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma. / Khattak, A.; Robert, C.; Blank, C. U.; Mandala, M.; Long, G. V.; Atkinson, V.; Dalle, S.; Haydon, A.; Lichinitser, M.; Carlino, M. S.; Sandhu, S.; Larkin, J.; Puig, S.; Ascierto, P. A.; Rutkowski, P.; Schadendorf, D.; Lorigan, P.; Ibrahim, N.; Suciu, S.; Eggermont, A. M. M.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 14, 08.2018, p. 48-48.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results

T2 - Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

AU - Khattak, A.

AU - Robert, C.

AU - Blank, C. U.

AU - Mandala, M.

AU - Long, G. V.

AU - Atkinson, V.

AU - Dalle, S.

AU - Haydon, A.

AU - Lichinitser, M.

AU - Carlino, M. S.

AU - Sandhu, S.

AU - Larkin, J.

AU - Puig, S.

AU - Ascierto, P. A.

AU - Rutkowski, P.

AU - Schadendorf, D.

AU - Lorigan, P.

AU - Ibrahim, N.

AU - Suciu, S.

AU - Eggermont, A. M. M.

PY - 2018/8

Y1 - 2018/8

M3 - Abstract/Meeting Abstract

VL - 14

SP - 48

EP - 48

JO - Asia–Pacific Journal of Clinical Oncology

JF - Asia–Pacific Journal of Clinical Oncology

SN - 1743-7555

ER -